Carregant...
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints
There is growing interest in integrated Phase I/II oncology clinical trials involving molecularly targeted agents (MTA). One of the main challenges of these trials are nontrivial dose–efficacy relationships and administration of MTAs in combination with other agents. While some designs were recently...
Guardat en:
| Publicat a: | Biom J |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899762/ https://ncbi.nlm.nih.gov/pubmed/31298770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201800313 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|